<?xml version="1.0" encoding="UTF-8"?>
<p>A newly developed CLIA allowed denaturation of the HBV particle, and used monoclonal antibodies against inner and outer structural epitopes in order to obtain higher assay sensitivity (
 <xref rid="hzw010C72" ref-type="bibr">Shinkai 
  <italic>et al</italic>., 2013
 </xref>) and sufficient information on the HBV genotypes.
</p>
